2 weeks Ago By Defense World Staff
Savara Inc ( NASDAQ:SVRA – Get Free Report ) shares reached a new 52-week low during mid-day trading on Thursday after HC Wainwright lowered their price target on the stock from $10.00 to $6.00.
HC Wainwright currently has a buy rating on the stock. Savara traded as low as $3.24 and last traded at $3.
32, with a volume of 128515 shares trading hands. The stock had previously closed at $3.25.
SVRA has been the subject of a number of other reports. Evercore ISI restated an “in-line” rating and set a $5.00 price objective (down from $7.
00) on shares of Savara in a research report on Wednesday. JMP Securities restated a “market outperform” rating and set a $9.00 price objective on shares of Savara in a research report on Tuesday, October 1st.
One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.17.
View Our Latest Analysis on SVRA Institutional Investors Weigh In On Savara Savara Price Performance The company has a debt-to-equity ratio of 0.26, a current ratio of 11.31 and a quick ratio of 11.
31. The stock’s fifty day moving average is $3.93 and its 200-day moving average is $4.
21. The stock has a market cap of $525.08 million, a PE ratio of -7.
60 and a beta of 1.02. Savara ( NASDAQ:SVRA – Get Free Report ) last announced its quarterly earnings data on Tuesday, November 12th.
The company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.11).
As a group, equities analysts anticipate that Savara Inc will post -0.44 EPS for the current year. Savara Company Profile ( Get Free Report ) Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company.
The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
See Also Five stocks we like better than Savara How to Start Investing in Real Estate 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick Most Volatile Stocks, What Investors Need to Know Mouse Rising: The Iger Investment Pays Off for Disney Investors Consumer Staples Stocks, Explained Can CAVA Stock Be the Next Chipotle? Earnings Can Help Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter ..
